Trial Profile
A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Ceftolozane/tazobactam (Primary) ; Levofloxacin
- Indications Gram-negative infections; Pseudomonal infections; Pyelonephritis; Urinary tract infections
- Focus Registrational; Therapeutic Use
- Acronyms ASPECT-cUTI
- Sponsors Cubist Pharmaceuticals
- 07 Oct 2018 Results presented at the IDWeek 2018
- 20 Dec 2016 Results of two studies (ASPECT-cIAI and ASPECT-cUTI) published in the Journal of Antimicrobial Chemotherapy
- 05 Oct 2016 Results of pooled analysis of this and two other phase 3 trials published in the Journal of Antimicrobial Chemotherapy (2016).